Immune Response to HPV Vaccine Among HIV-1-infected Subjects in Brazil

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02236234

Acronym

HPV

Enrollment

Registered

2014-09-10

Start date

2012-01-31

Completion date

2014-01-31

Last updated

2014-09-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infection

Keywords

HIV, HPV, Clinical trial, outcome

Brief summary

Besides the specific response to vaccine antigens, the investigators will analyze the anti-HPV immune response in HIV-1-infected men in different strata of immune deficiency. The hypothesis will be tested by stratification by T CD4 + lymphocytes in an attempt to assess the range of the count with the highest possibility of vaccine response. Thus, knowledge of vaccine response in HIV-infected patients, indicate which patients would have greater potential for vaccine response in vivo.

Detailed description

The study will be divided into three groups. Patients with HIV-1 infection will be subdivided into groups according to T CD4 + lymphocytes at the time of vaccination: Over 500 CD4 T cells count and bellow 500 CD4 T cells count. A healthy control group will be also studied.

Interventions

BIOLOGICALHPV vaccine

HPV vaccine

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

MALE

Age

35 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

HIV * Men with age between 35 and 45 years of age.

Exclusion criteria

* Current or previous infection with human papillomavirus (HPV)

Design outcomes

Primary

Measure	Time frame	Description
Presence of Anti-HPV antibody titers	0, 30 and 180 days of vaccination anti-HPV	The anti-HPV titers will be compared from baseline to the date of sample collection

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026